BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Disopyramide

Mortality Risk

  • In the National Heart, Lung and Blood Institutie's Cardiac Arrythmia Suppression Trial (CAST), a long-term, multi-center, randomized, double blind study in patients with asymptomatic non-life-threatening ventricular arrhythmias who had a myocardial infarction more than 6 days but less than 2 years previously, an excessive mortality or non-fatal cardiac arrest rate (7.7%) was seen in patients treated with encainide or flecainide compared with that seen in patients assigned to carefully matched placebo treated groups (3%). The average duration of treatment with encainide or flecainide in this study was 10 months.
  • The applicability of the CAST results to other populations (e.g., those without recent myocardial infarction) is uncertain. Considering the known proarrhythmic properties of disopyramide and the lack of evidence of improved survival for any antiarrhymic drug in patients without life-threatening arrhythmias, the use of disopyramide as well as other antiarrhythmic agents should be reserved for patients with life-threatening ventricular arrhythmias.

Package Inserts

Disopyramide

Additional Information

Updated January 2018